Bectumomab
Modify Date: 2024-01-03 11:25:05
Bectumomab structure
|
Common Name | Bectumomab | ||
|---|---|---|---|---|
| CAS Number | 158318-63-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BectumomabBectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunotherapy (RIT)[1]. |
| Name | Bectumomab |
|---|
| Description | Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunotherapy (RIT)[1]. |
|---|---|
| Related Catalog | |
| Target |
CD22[1] |
| In Vitro | Bectumomab 可与小鼠单克隆免疫球蛋白 LL-2 轻链二硫化形成二聚体[1]。 |
| References |
| No Any Chemical & Physical Properties |